Showing results (901-910 of 1,191) with videos related to

Sort By:
Pageof 120
American Journal of Hematology|June 26, 2019
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenibFevzi Yalniz, Iman Abou Dalle, Hagop Kantarjian, et al.
Cancer|December 2, 2022
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemiaAlexandre Bazinet, Faezeh Darbaniyan, Tapan M Kadia, et al.
Leukemia Research|August 23, 2024
Characteristics and outcomes of children, adolescent, and young adult patients with myelodysplastic neoplasms: A single-center retrospective analysisDavid McCall, Tareq Abuasab, Juan Jose Rodriguez-Sevilla, et al.
Blood Advances|September 15, 2021
Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experienceGuillaume Richard-Carpentier, Hagop M Kantarjian, Guilin Tang, et al.
The Lancet. Haematology|May 8, 2019
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trialGuillermo Garcia-Manero, Gail Roboz, Katherine Walsh, et al.
Blood|August 27, 2005
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer CenterYasuhiro Oki, Hagop M Kantarjian, Xian Zhou, et al.
JAMA Oncology|September 1, 2017
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical TrialElias Jabbour, Farhad Ravandi, Partow Kebriaei, et al.
Blood Cancer Journal|September 30, 2021
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangementsGhayas C Issa, Jabra Zarka, Koji Sasaki, et al.
Leukemia & Lymphoma|September 12, 2022
Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatmentHussein A Abbas, Edward Ayoub, Hanxiao Sun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylateHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
Pageof 120